Zr Pharma Company Profile

✉ Email this page to a colleague

ZR PHARMA has one approved drug.

There are eleven US patents protecting ZR PHARMA drugs.

There are two hundred and six patent family members on ZR PHARMA drugs in forty-two countries and thirty-one supplementary protection certificates in eighteen countries.

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zr Pharma	RUBRACA	rucaparib camsylate	TABLET;ORAL	209115-003	May 1, 2017		RX	Yes	No	10,278,974	⤷ Try a Trial	Y			⤷ Try a Trial
Zr Pharma	RUBRACA	rucaparib camsylate	TABLET;ORAL	209115-002	Dec 19, 2016		RX	Yes	Yes	8,071,579	⤷ Try a Trial				⤷ Try a Trial
Zr Pharma	RUBRACA	rucaparib camsylate	TABLET;ORAL	209115-002	Dec 19, 2016		RX	Yes	Yes	8,859,562	⤷ Try a Trial				⤷ Try a Trial
Zr Pharma	RUBRACA	rucaparib camsylate	TABLET;ORAL	209115-002	Dec 19, 2016		RX	Yes	Yes	9,987,285	⤷ Try a Trial	Y			⤷ Try a Trial
Zr Pharma	RUBRACA	rucaparib camsylate	TABLET;ORAL	209115-001	Dec 19, 2016		RX	Yes	No	7,531,530	⤷ Try a Trial				⤷ Try a Trial
Zr Pharma	RUBRACA	rucaparib camsylate	TABLET;ORAL	209115-001	Dec 19, 2016		RX	Yes	No	8,754,072	⤷ Try a Trial	Y	Y		⤷ Try a Trial
Zr Pharma	RUBRACA	rucaparib camsylate	TABLET;ORAL	209115-002	Dec 19, 2016		RX	Yes	Yes	10,130,636	⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Zr Pharma	RUBRACA	rucaparib camsylate	TABLET;ORAL	209115-001	Dec 19, 2016	6,495,541	⤷ Try a Trial
Zr Pharma	RUBRACA	rucaparib camsylate	TABLET;ORAL	209115-003	May 1, 2017	6,495,541	⤷ Try a Trial
Zr Pharma	RUBRACA	rucaparib camsylate	TABLET;ORAL	209115-002	Dec 19, 2016	6,495,541	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration
Japan	2015131858	⤷ Try a Trial
South Korea	20190026043	⤷ Try a Trial
World Intellectual Property Organization (WIPO)	2005053662	⤷ Try a Trial
Israel	249946	⤷ Try a Trial
Mexico	PA06006120	⤷ Try a Trial
Brazil	PI0412899	⤷ Try a Trial
Netherlands	300958	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1633724	2015/016	Ireland	⤷ Try a Trial	PRODUCT NAME: OLAPARIB, AND SALTS AND SOLVATES THEREOF; REGISTRATION NO/DATE: EU/1/14/959/001 20141216
2534153	300958	Netherlands	⤷ Try a Trial	PRODUCT NAME: RUCAPARIB CAMSYLAAT; REGISTRATION NO/DATE: EU/1/17/1250 20180529
1633724	15C0022	France	⤷ Try a Trial	PRODUCT NAME: OLAPARIB,SELS ET SOLVATES DE CELUI-CI; REGISTRATION NO/DATE: EU 1/14/959 20141218
1633724	92680	Luxembourg	⤷ Try a Trial	PRODUCT NAME: OLAPARIB AINSI QUE DES SELS ET DES SOLVATES DE CELUI-CI. FIRST REGISTRATION: 20141218
2534153	2018C/044	Belgium	⤷ Try a Trial	PRODUCT NAME: RUCAPARIB-CAMSYLAAT; AUTHORISATION NUMBER AND DATE: EU/1/17/1250 20180529
2534153	CA 2018 00041	Denmark	⤷ Try a Trial	PRODUCT NAME: RUCAPARIB CAMSYLATE; REG. NO/DATE: EU/1/17/1250/001-003 20180529
1633724	C 2015 011	Romania	⤷ Try a Trial	PRODUCT NAME: OLAPARIB; NATIONAL AUTHORISATION NUMBER: EU/1/14/959/001; DATE OF NATIONAL AUTHORISATION: 20141216; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/959/001; DATE OF FIRST AUTHORISATION IN EEA: 20141216
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.